Changes in Liver Function Tests (LFTs) with Canagliflozin (CANA) vs. Sitagliptin (SITA) in Patients with Type 2 Diabetes Mellitus (T2DM) Are Related to Changes in A1c and Body Weight (BW)

被引：0

|

作者：

Leiter, Lawrence A.

Forst, Thomas

Polidori, David

Balis, Dainius

Xie, John

Sha, Sue

机构：

来源：

DIABETES | 2015年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1265-P

引用

收藏

页码：A328 / A328

页数：1

相关论文

共 50 条

[31] Canagliflozin (CANA) Improves Glycemic Control and Reduces Body Weight and Blood Pressure (BP) in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) With or Without Other Antihyperglycemic Agents (AHAs)
Hollander, Priscilla
Mathieu, Chantal
Tong, Cindy
Canovatchel, William
Meininger, Gary
[J]. DIABETES, 2015, 64 : A662 - A663
[32] Comparison of Hospitalization for Heart Failure (HHF) among Patients with Type 2 Diabetes Mellitus (T2DM) and Macroalbuminuria Initiated on Canagliflozin (CANA) or a DPP-4
Pilon, Dominic
Durkin, Michael
Manceur, Ameur
Ghelerter, Isabelle
Lafeuille, Marie-Hel
Lefebvre, Patrick
[J]. DIABETES, 2020, 69
[33] GROWTH MIXTURE MODELING (GMM) TO DETERMINE TREATMENT EFFECTS OF CANAGLIFLOZIN VERSUS SITAGLIPTIN ON WEIGHT-RELATED QUALITY OF LIFE (WRQOL) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Stull, D. E.
Houghton, K.
Traina, S. B.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A447 - A447
[34] The Role of Estimated Glomerular Filtration Rate (eGFR) in Cost-Effectiveness (CE) Analyses Using Canagliflozin (CANA) vs. Sulfonylurea (SU) to Treat Type 2 Diabetes Mellitus (T2DM)
Neslusan, Cheryl
Willis, Michael
Johansen, Pierre
Schroeder, Melanie
Nilsson, Andreas
Chan, Edmond
Asseburg, Christian
Schubert, Agata
[J]. DIABETES, 2016, 65 : A329 - A329
[35] The Changes of Leukocyte Telomere Length after Different Treatments in Patients with Type 2 Diabetes Mellitus (T2DM)
Liu, Juanhong
Ma, Delin
Yang, Yan
[J]. DIABETES, 2018, 67
[36] Sitagliptin (SITA) Provides Similar Glycemic Control with Weight Loss and Less Hypoglycemia Compared to Sulfonylurea (SU) in Older Patients with Type 2 Diabetes (T2DM)
Seck, Thomas
Engel, Samuel S.
Chen, Yu
Golm, Gregory T.
Davies, Michael J.
Kaufman, Keith D.
Goldstein, Barry
[J]. DIABETES, 2011, 60 : A620 - A621
[37] Modelling HbA1c Trajectory in Patients with Type 2 Diabetes Mellitus (T2DM)
Mcewan, Phil
Fellows, Jonathan
Yapp, Rhiannon
Bergenheim, Klas
Qin, Lei
Varol, Nebibe
Bennett, Hayley
Gordon, Jason
[J]. DIABETES, 2016, 65 : A322 - A322
[38] Efficacy and safety of canagliflozin (CANA) in patients with type 2 diabetes mellitus (T2DM) who progressed to stage 3A chronic kidney disease during treatment
Roussel, R.
de Zeeuw, D.
Law, G.
Meininger, G.
[J]. DIABETOLOGIA, 2014, 57 : S322 - S323
[39] Saxagliptin (SAXA) Reduces A1C and Is Well Tolerated in Patients With Type 2 Diabetes (T2DM) and Albuminuria
Bonora, Enzo
Cook, William
Bryzinski, Brian
Hirshberg, Boaz
Allen, Elsie
[J]. DIABETES, 2013, 62 : A669 - A669
[40] Glycemic control and safety of insulin glargine (GLAR) in elderly patients with type 2 diabetes mellitus (T2DM): The GOAL A1C study
Halter, Jeffrey B.
Kennedy, Laurence
Herman, William H.
Miller, Michael E.
[J]. DIABETES, 2006, 55 : A114 - A115

← 1 2 3 4 5 →